Company facts
- Headquarters
- Frankfurt Am Main
- Most recent report
- 6-K, filed May 19, 2026
- Filings on record
- 43 filings
- On EDGAR
- CIK 1982708
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Emerging growth company
Financials 8 of 9
- 6-K Report a foreign issuer made public elsewhere May 19, 2026
- 6-K Report a foreign issuer made public elsewhere Apr 27, 2026
- 20-F Annual report, foreign issuer Apr 7, 2026
- 6-K Report a foreign issuer made public elsewhere Feb 17, 2026
- 6-K Report a foreign issuer made public elsewhere Jan 26, 2026
- 6-K Report a foreign issuer made public elsewhere Dec 30, 2025
- 6-K Report a foreign issuer made public elsewhere Nov 13, 2025
- 20-F Annual report, foreign issuer Apr 28, 2025
Prospectuses and Registrations 3
Ownership 7
- 3 Insider reported their initial holding Jun 12, 2026
- 3 Insider reported their initial holding Jun 12, 2026
- 3 Insider reported their initial holding Apr 8, 2026
- 3 Insider reported their initial holding Apr 8, 2026
- 3 Insider reported their initial holding Apr 8, 2026
- 3 Insider reported their initial holding Apr 8, 2026
- 3 Insider reported their initial holding Apr 8, 2026
Other 8 of 24
- F-3ASR Jul 9, 2026
- 20-F/A Annual report, foreign issuer, amended Apr 9, 2026
- EFFECT Notice that a registration became effective Feb 18, 2025
- CERT Exchange certified a listing Feb 18, 2025
- CORRESP Reply to SEC staff Feb 14, 2025
- CORRESP Reply to SEC staff Feb 14, 2025
- 8-A12B Registration of a security for exchange listing Feb 14, 2025
- F-1/A Registration statement, foreign issuer, amended Feb 10, 2025
Everything here comes from Anbio Biotechnology's own filings on SEC EDGAR. The filing list is rechecked every hour.